Bashan Dror
SEC insider (Form 3/4/5 filer). CIK 0001781450. PRESIDENT AND CEO at Protalix BioTherapeutics, Inc. (PLX). 4 reported Form 4/5 transactions since Sep 2024; latest on Sep 3, 2026. Located in CARMIEL.
Companies Bashan Dror has filed insider reports for
- Protalix BioTherapeutics, Inc. (PLX): Director, Officer, PRESIDENT AND CEO
Bashan Dror
CIK: 0001781450
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Protalix BioTherapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Sep 3, 2026PLX
Protalix BioTherapeutics, Inc.
AwardDirectStock Option (Right to Buy)
320K shares- - Sep 3, 2026PLX
Protalix BioTherapeutics, Inc.
AwardDirectRestricted Stock Units
160K shares- - Dec 19, 2025PLX
Protalix BioTherapeutics, Inc.
PurchaseDirect56K shares at avg. $1.81$101K - Sep 3, 2025PLX
Protalix BioTherapeutics, Inc.
AwardIndirect195K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 3, 2026 | PLX Protalix BioTherapeutics, Inc. | Award Stock Option (Right to Buy) | 320,000 | - | - | Direct |
| Sep 3, 2026 | PLX Protalix BioTherapeutics, Inc. | Award Restricted Stock Units | 160,000 | - | - | Direct |
| Dec 19, 2025 | PLX Protalix BioTherapeutics, Inc. | Purchase | 56,000 | $1.81 | $101,360 | Direct |
| Sep 3, 2025 | PLX Protalix BioTherapeutics, Inc. | Award | 195,000 | - | - | Indirect |
1-4 of 4 transactions